WO2010107964A1 - Unit doses, aerosols, kits, and methods for treating heart conditions by pulmonary administration - Google Patents

Unit doses, aerosols, kits, and methods for treating heart conditions by pulmonary administration Download PDF

Info

Publication number
WO2010107964A1
WO2010107964A1 PCT/US2010/027740 US2010027740W WO2010107964A1 WO 2010107964 A1 WO2010107964 A1 WO 2010107964A1 US 2010027740 W US2010027740 W US 2010027740W WO 2010107964 A1 WO2010107964 A1 WO 2010107964A1
Authority
WO
WIPO (PCT)
Prior art keywords
antiarrhythmic
pharmaceutical agent
class
antiarrhythmic pharmaceutical
administering
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2010/027740
Other languages
English (en)
French (fr)
Inventor
Carlos A. Schuler
Rangachari Narasimhan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
PLEIADES CARDIO-THERAPEUTICS Inc
Original Assignee
PLEIADES CARDIO-THERAPEUTICS Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to EP10754091.6A priority Critical patent/EP2413902B1/en
Priority to EP19176305.1A priority patent/EP3552603B1/en
Priority to EP19176272.3A priority patent/EP3552602B1/en
Priority to DK10754091.6T priority patent/DK2413902T3/da
Priority to PL10754091T priority patent/PL2413902T3/pl
Priority to AU2010226613A priority patent/AU2010226613B2/en
Priority to CA2755809A priority patent/CA2755809C/en
Priority to ES10754091T priority patent/ES2750359T3/es
Priority to JP2012500945A priority patent/JP2012520890A/ja
Application filed by PLEIADES CARDIO-THERAPEUTICS Inc filed Critical PLEIADES CARDIO-THERAPEUTICS Inc
Priority to US13/257,249 priority patent/US8974828B2/en
Publication of WO2010107964A1 publication Critical patent/WO2010107964A1/en
Anticipated expiration legal-status Critical
Priority to US14/632,252 priority patent/US10045939B2/en
Priority to US16/013,178 priority patent/US20180318213A1/en
Priority to US16/013,165 priority patent/US20180296480A1/en
Priority to US16/172,456 priority patent/US20190060230A1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4458—Non condensed piperidines, e.g. piperocaine only substituted in position 2, e.g. methylphenidate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M11/00—Sprayers or atomisers specially adapted for therapeutic purposes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics

Definitions

  • Paroxysmal atrial fibrillation is a subset of the overall atrial fibrillation (AF) population and is estimated to be 25-30% of the overall AF population. About 2.5 million patients are affected by AF in the United States. The population of PAF patients is estimated to be 900,000 to 1.5 million worldwide.
  • minimum effective amount means the minimum amount necessary to achieve an effective amount.
  • MMAD mass median aerodynamic diameter
  • the “aerodynamic diameter” is the diameter of a unit density sphere having the same settling velocity, generally in air, as a powder and is therefore a useful way to characterize an aerosolized powder or other dispersed particle or particle formulation in terms of its settling behavior.
  • the aerodynamic diameter encompasses particle or particle shape, density, and physical size of the
  • kits comprises a container containing at least one antiarrhythmic pharmaceutical agent and an aerosolization device.
  • the present invention includes "pharmaco- rescue-therapies" to provide fast cardioversion in patients with atrial arrhythmias like Paroxysmal Ventricular Tachycardia (PSVT), and Paroxysmal Atrial Fibrillation (PAF).
  • PSVT Paroxysmal Ventricular Tachycardia
  • PAF Paroxysmal Atrial Fibrillation
  • the pharmaco-rescue-therapies are usually intended for self-administration of the medicine by inhalation.
  • the present invention involves low doses that are safe and effective. Other aspects typically involve low premature metabolism and low drug-drug interaction.
  • FSH follicle
  • carbohydrates include, but are not limited to, monosaccharides, disaccharides, and polysaccharides.
  • monosaccharides such as dextrose (anhydrous and monohydrate), galactose, mannitol, D-mannose, sorbitol, sorbose and the like; disaccharides such as lactose, maltose, sucrose, trehalose, and the like; trisaccharides such as raffinose and the like; and other carbohydrates such as starches (hydroxyethylstarch), cyclodextrins, and maltodextrins.
  • incorporation of the phospholipid in bilayer form may be used, especially if the active agent is encapsulated therein.
  • increasing the T m of the phospholipid may provide benefit via incorporation of divalent counterions or cholesterol.
  • increasing the interaction between the phospholipid and drug substance via the formation of ion-pairs negatively charged active+steaylamine, positively charged active+phosphatidylglycerol
  • the active is amphiphilic, surfactant/surfactant interactions may also slow active dissolution.
  • the batch may be filtered, e.g., through a 0.2 ⁇ m filter into a sterilized receiving vessel. Filling components may be sterilized before use in filling the batch into vials, e.g., 10 ml vials.
  • the above-noted filtration may involve filtration into a laminar flow work area.
  • the receiving bottle and filters may be set up in the laminar flow work area.
  • the lyophilizing is generally conducted within about 72 hours, such as within about 8 hours, or within about 4 hours, of the dissolving.
  • predetermined temperature for a period ranging from about 20 hours to about 30 hours, such as from about 24 hours.
  • the lyophilization cycle may comprise a freezing ramp, e.g., from 20 0 C to -45°C in 65 minutes, followed by a freeze soak, e.g., at - 45°C for 2 hours.
  • Primary drying may be accomplished with a heating ramp, e.g., from -45°C to 15°C in 8 hours, followed by a temperature hold, e.g., at 15°C for 24 hours at a pressure of 200 ⁇ bar.
  • Secondary drying may be accomplished with a heating ramp, e.g., from 15°C to 30 0 C in 15 minutes, followed by a temperature hold at 30 0 C for 15 hours at a pressure of 200 ⁇ bar.
  • the vacuum may be broken with sterile nitrogen, and the vials may be automatically stoppered.
  • the dosing may be guided by how the patient feels. Also or alternatively, dosing may be guided by a portable ECG. For instance, the dosing may be guided by a Holter monitor.
  • the pharmaceutical composition may be administered to a patient in any regimen which is effective to prevent an arrhythmia.
  • Illustrative prophylactic regimes include administering an antiarrhythmic pharmaceutical agent as described herein 1 to 21 times per week.
  • the systemic exposure of the antiarrhythmic pharmaceutical agent can be reduced by avoiding initial dilution.
  • the antiarrhythmic pharmaceutical agent undergoes dilution as and after it passes through the heart.
  • the dispersions or powder pharmaceutical compositions may be administered using an aerosolization device.
  • the aerosolization device may be a nebulizer, a metered dose inhaler, a liquid dose instillation device, or a dry powder inhaler.
  • the pharmaceutical composition may be delivered by a nebulizer as described in WO 99/16420, by a metered dose inhaler as described in WO 99/16422, by a liquid dose instillation apparatus as described in WO 99/16421 , and by a dry powder inhaler as described in U.S. Published Application Nos. 20020017295 and 20040105820, WO 99/16419, WO 02/83220, and U.S. Pat. No. 6,546,929, which are incorporated herein by reference in their entireties.
  • a nebulizer as described in WO 99/16420
  • a metered dose inhaler as described in WO 99/16422
  • a liquid dose instillation apparatus as described in WO 99/164
  • doses of the pharmaceutical composition may be delivered using a variety of aerosolization devices and techniques.
  • kits may include an aerosolization device and a container, e.g., unit dose receptacle, containing aerosolizable antiarrhythmic pharmaceutical agent, e.g., liquid or dry powder.
  • a container e.g., unit dose receptacle, containing aerosolizable antiarrhythmic pharmaceutical agent, e.g., liquid or dry powder.
  • a cut-down on a jugular vein permitted the introduction of a pacing lead into the right atrium.
  • a solid-state micromanometer catheter (Millar Instruments) was advanced into the aortic root via a cut-down over an artery (e.g., femoral, carotid).
  • Transthoracic electrodes forming ECG lead Il was placed.
  • a 4F catheter was introduced through the trachea and wedged into a small airway, and a venous catheter was placed in a peripheral vessel (i.e., cephalic).

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dispersion Chemistry (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PCT/US2010/027740 2009-03-18 2010-03-18 Unit doses, aerosols, kits, and methods for treating heart conditions by pulmonary administration Ceased WO2010107964A1 (en)

Priority Applications (14)

Application Number Priority Date Filing Date Title
JP2012500945A JP2012520890A (ja) 2009-03-18 2010-03-18 経肺投与によって心疾患を治療するための単位用量、エアロゾル、キット、および方法
EP19176272.3A EP3552602B1 (en) 2009-03-18 2010-03-18 Unit doses, aerosols, kits, and methods for treating heart conditions by pulmonary administration
DK10754091.6T DK2413902T3 (da) 2009-03-18 2010-03-18 Enhedsdoser, aerosoler, kits og fremgangsmåder til behandling af hjertetilstande ved pulmonal indgivelse
PL10754091T PL2413902T3 (pl) 2009-03-18 2010-03-18 Dawki jednostkowe, aerozole, zestawy oraz sposoby leczenia chorób serca przez podawanie dopłucne
AU2010226613A AU2010226613B2 (en) 2009-03-18 2010-03-18 Unit doses, aerosols, kits, and methods for treating heart conditions by pulmonary administration
CA2755809A CA2755809C (en) 2009-03-18 2010-03-18 Unit doses, aerosols, kits, and methods for treating heart conditions by pulmonary administration
ES10754091T ES2750359T3 (es) 2009-03-18 2010-03-18 Dosis unitarias, aerosoles, kits y procedimientos para tratar afecciones cardíacas mediante administración pulmonar
EP10754091.6A EP2413902B1 (en) 2009-03-18 2010-03-18 Unit doses, aerosols, kits, and methods for treating heart conditions by pulmonary administration
US13/257,249 US8974828B2 (en) 2009-03-18 2010-03-18 Unit doses, aerosols, kits, and methods for treating heart conditions by pulmonary administration
EP19176305.1A EP3552603B1 (en) 2009-03-18 2010-03-18 Unit doses, aerosols, kits, and methods for treating heart conditions by pulmonary administration
US14/632,252 US10045939B2 (en) 2009-03-18 2015-02-26 Unit doses, aerosols, kits, and methods for treating heart conditions by pulmonary administration
US16/013,178 US20180318213A1 (en) 2009-03-18 2018-06-20 Unit doses, aerosols, kits, and methods for treating heart conditions by pulmonary administration
US16/013,165 US20180296480A1 (en) 2009-03-18 2018-06-20 Unit doses, aerosols, kits, and methods for treating heart conditions by pulmonary administration
US16/172,456 US20190060230A1 (en) 2009-03-18 2018-10-26 Unit doses, aerosols, kits, and methods for treating heart conditions by pulmonary administration

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US21038209P 2009-03-18 2009-03-18
US61/210,382 2009-03-18

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US13/257,249 A-371-Of-International US8974828B2 (en) 2009-03-18 2010-03-18 Unit doses, aerosols, kits, and methods for treating heart conditions by pulmonary administration
US14/632,252 Continuation US10045939B2 (en) 2009-03-18 2015-02-26 Unit doses, aerosols, kits, and methods for treating heart conditions by pulmonary administration

Publications (1)

Publication Number Publication Date
WO2010107964A1 true WO2010107964A1 (en) 2010-09-23

Family

ID=42739985

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2010/027740 Ceased WO2010107964A1 (en) 2009-03-18 2010-03-18 Unit doses, aerosols, kits, and methods for treating heart conditions by pulmonary administration

Country Status (9)

Country Link
US (5) US8974828B2 (enExample)
EP (3) EP3552602B1 (enExample)
JP (5) JP2012520890A (enExample)
AU (1) AU2010226613B2 (enExample)
CA (2) CA2835771C (enExample)
DK (1) DK2413902T3 (enExample)
ES (3) ES2750359T3 (enExample)
PL (1) PL2413902T3 (enExample)
WO (1) WO2010107964A1 (enExample)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016118625A1 (en) * 2015-01-20 2016-07-28 Incarda Therapeutics, Inc. Unit aerosol doses for anticoagulation
US10045939B2 (en) 2009-03-18 2018-08-14 Incarda Therapeutics, Inc. Unit doses, aerosols, kits, and methods for treating heart conditions by pulmonary administration
WO2018209107A1 (en) 2017-05-10 2018-11-15 Incarda Therapeutics, Inc. Unit doses, aerosols, kits, and methods for treating heart conditions by pulmonary administration
EP3283067A4 (en) * 2015-04-14 2018-12-05 Milestone Pharmaceuticals Inc. Highly water-soluble salts of a short acting phenylalkylamine calcium channel blocker and uses thereof
US10660578B2 (en) 2016-02-01 2020-05-26 Incarda Therapeutics, Inc. Combining electronic monitoring with inhaled pharmacological therapy to manage cardiac arrhythmias including atrial fibrillation
US10744087B2 (en) 2018-03-22 2020-08-18 Incarda Therapeutics, Inc. Method to slow ventricular rate
US11007185B2 (en) 2019-08-01 2021-05-18 Incarda Therapeutics, Inc. Antiarrhythmic formulation
US12059414B2 (en) 2020-12-17 2024-08-13 Incarda Therapeutics, Inc. Kits and methods for induction of cardioversion in subjects with atrial arrhythmias

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2654864B1 (en) 2010-12-22 2020-10-28 Syqe Medical Ltd. System for drug delivery
US9713687B2 (en) 2012-08-21 2017-07-25 Philip Morris Usa Inc. Ventilator aerosol delivery system with transition adapter for introducing carrier gas
US11191755B2 (en) 2014-01-17 2021-12-07 Cornell University Compositions and methods for providing cardioprotective effects
TWI590837B (zh) * 2014-03-25 2017-07-11 林信湧 一種用於治療心臟病之吸入式醫藥組成物及其備製方法
CN106604755B (zh) 2014-06-30 2020-08-11 Syqe医药有限公司 流量调节的吸入器装置
EP3160565B1 (en) * 2014-06-30 2021-08-18 Syqe Medical Ltd. Devices and systems for pulmonary delivery of active agents
US11298477B2 (en) 2014-06-30 2022-04-12 Syqe Medical Ltd. Methods, devices and systems for pulmonary delivery of active agents
ES2874087T3 (es) 2016-01-06 2021-11-04 Syqe Medical Ltd Tratamiento terapéutico con dosis bajas
US20210228825A1 (en) * 2018-06-05 2021-07-29 Incarda Therapeutics, Inc. Methods for diagnosing brugada syndrome using an aerosol
WO2019241597A1 (en) * 2018-06-14 2019-12-19 Cornell University Compositions and methods for providing cardioprotective effects
US12396970B2 (en) 2021-08-20 2025-08-26 AltaThera Pharmaceuticals LLC Anti-arrhythmic compositions and methods
US10512620B1 (en) 2018-08-14 2019-12-24 AltaThera Pharmaceuticals, LLC Method of initiating and escalating sotalol hydrochloride dosing
US11696902B2 (en) 2018-08-14 2023-07-11 AltaThera Pharmaceuticals, LLC Method of initiating and escalating sotalol hydrochloride dosing
US11344518B2 (en) * 2018-08-14 2022-05-31 AltaThera Pharmaceuticals LLC Method of converting atrial fibrillation to normal sinus rhythm and loading oral sotalol in a shortened time frame
US11610660B1 (en) 2021-08-20 2023-03-21 AltaThera Pharmaceuticals LLC Antiarrhythmic drug dosing methods, medical devices, and systems
KR102891439B1 (ko) * 2019-08-01 2025-11-25 인카다 테라퓨틱스, 인크. 항부정맥 제제

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060034847A1 (en) 2004-08-11 2006-02-16 Yun Anthony J Methods of treating a subject for a condition
WO2007050347A1 (en) 2005-10-21 2007-05-03 Merck & Co., Inc. Potassium channel inhibitors
US20070122353A1 (en) 2001-05-24 2007-05-31 Hale Ron L Drug condensation aerosols and kits
WO2008036247A1 (en) 2006-09-18 2008-03-27 Vitae Pharmaceuticals, Inc. Renin inhibitors
WO2008072190A2 (en) 2006-12-15 2008-06-19 The Procter & Gamble Company Compositions of azimilide dihydrochloride
US20080275036A1 (en) * 2007-05-02 2008-11-06 Apt Pharmaceuticals, Inc. Prevention and treatment of cardiac conditions
WO2008134630A1 (en) 2007-04-30 2008-11-06 Apt Pharmaceuticals Dexrazoxane compounds for cardioprotection
WO2010019914A2 (en) 2008-08-14 2010-02-18 The Uab Research Foundation Anti-arrhythmia agents, methods of their use, methods for their identification, and kits thereofre
WO2010022259A1 (en) 2008-08-22 2010-02-25 Milestone Pharmaceuticals Inc. Short acting benzothiazepine calcium channel blockers and uses thereof

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4069819A (en) 1973-04-13 1978-01-24 Societa Farmaceutici S.P.A. Inhalation device
IT1016489B (it) 1974-03-18 1977-05-30 Isf Spa Inalatore
SE408265B (sv) 1975-12-12 1979-06-05 Draco Ab Anordning for koldioxiddriven endosaerosol, avsedd for inhalering
US4247066A (en) 1978-02-21 1981-01-27 General Dynamics Corporation Airfoil variable cambering device and method
IT1116047B (it) 1979-04-27 1986-02-10 Sigma Tau Ind Farmaceuti Dispositivo per la rapida inalazione di farmaci in polvere da parte di persone sofferenti di asma
DE3634952A1 (de) 1986-10-14 1988-04-21 Bayer Ag Imidazo-pyrrolo-pyridin-derivate
JP3202705B2 (ja) * 1987-11-06 2001-08-27 リサーチ ディベロップメント ファンデーション 医療用のリポソームおよび薬物含有リポソームのエアゾールの小粒子
US4962095A (en) * 1989-02-15 1990-10-09 E. R. Squibb & Sons, Inc. Method of reducing pre-and post-ischemic myocardial arrhythmias and fibrillation
IT1228459B (it) 1989-02-23 1991-06-19 Phidea S R L Inalatore con svuotamento regolare e completo della capsula.
EP0940154B1 (en) 1991-07-02 2007-04-18 Nektar Therapeutics Device for delivering aerosolized medicaments
US6582728B1 (en) 1992-07-08 2003-06-24 Inhale Therapeutic Systems, Inc. Spray drying of macromolecules to produce inhaleable dry powders
US5785049A (en) 1994-09-21 1998-07-28 Inhale Therapeutic Systems Method and apparatus for dispersion of dry powder medicaments
KR100419037B1 (ko) 1994-03-07 2004-06-12 넥타르 테라퓨틱스 폐를통한인슐린의전달방법및그조성물
US6051256A (en) 1994-03-07 2000-04-18 Inhale Therapeutic Systems Dispersible macromolecule compositions and methods for their preparation and use
AU696387B2 (en) 1994-05-18 1998-09-10 Inhale Therapeutic Systems, Inc. Methods and compositions for the dry powder formulation of interferons
JP3388896B2 (ja) 1994-08-08 2003-03-24 株式会社日立ユニシアオートモティブ 吸入式投薬器
US5693609A (en) 1994-11-17 1997-12-02 Eli Lilly And Company Acylated insulin analogs
ATE287703T1 (de) 1995-04-14 2005-02-15 Nektar Therapeutics Pulverförmige pharmazeutische formulierungen mit verbesserter dispergierbarkeit
US5855913A (en) 1997-01-16 1999-01-05 Massachusetts Instite Of Technology Particles incorporating surfactants for pulmonary drug delivery
US6503480B1 (en) 1997-05-23 2003-01-07 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
US5874064A (en) 1996-05-24 1999-02-23 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
US5985309A (en) 1996-05-24 1999-11-16 Massachusetts Institute Of Technology Preparation of particles for inhalation
US5976574A (en) 1996-12-31 1999-11-02 Inhale Therapeutic Systems Processes for spray drying hydrophobic drugs in organic solvent suspensions
US20020017295A1 (en) 2000-07-07 2002-02-14 Weers Jeffry G. Phospholipid-based powders for inhalation
KR100575070B1 (ko) 1997-09-29 2006-05-03 넥타르 테라퓨틱스 안정화된 생활성 제제 및 이의 사용 방법
WO1999016420A1 (en) 1997-09-29 1999-04-08 Inhale Therapeutic Systems, Inc. Stabilized preparations for use in nebulizers
US6541479B1 (en) * 1997-12-02 2003-04-01 Massachusetts College Of Pharmacy Calcium channel blockers
US6257233B1 (en) 1998-06-04 2001-07-10 Inhale Therapeutic Systems Dry powder dispersing apparatus and methods for their use
DE19835346A1 (de) 1998-08-05 2000-02-10 Boehringer Ingelheim Pharma Zweiteilige Kapsel zur Aufnahme von pharmazeutischen Zubereitungen für Pulverinhalatoren
IL143046A0 (en) 1998-11-12 2002-04-21 Pilkiewicz Frank G An inhalation system
ATE422924T1 (de) 1999-05-28 2009-03-15 Nektar Therapeutics Gerät zum abgeben von abgemessenen mengen von medikamente beinhaltendem aerosol
CA2406206C (en) * 2000-04-17 2012-03-20 Vectura Limited Improvements in or relating to formulations for use in inhaler devices
PT1280520E (pt) 2000-05-10 2014-12-16 Novartis Ag Pós à base de fosfolípidos para administração de fármacos
US7871598B1 (en) 2000-05-10 2011-01-18 Novartis Ag Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use
US6357490B1 (en) 2000-08-22 2002-03-19 Advanced Inhalation Research, Inc. System, method and apparatus for filling containers
FI20002215A0 (fi) * 2000-10-06 2000-10-06 Orion Yhtymae Oyj Yhdistelmäpartikkelit
EP1343372A2 (en) 2000-12-21 2003-09-17 Nektar Therapeutics Pulmonary delivery of polyene antifungal agents
BR0208012A (pt) 2001-03-20 2004-03-02 Glaxo Group Ltd Usos de pelo menos duas drogas e um propelente hfa e de pelo menos uma composição farmaceêutica, e, inalador acondicionado para tratar asma
US6766799B2 (en) 2001-04-16 2004-07-27 Advanced Inhalation Research, Inc. Inhalation device
US7090830B2 (en) * 2001-05-24 2006-08-15 Alexza Pharmaceuticals, Inc. Drug condensation aerosols and kits
EP1392262A1 (en) * 2001-05-24 2004-03-03 Alexza Molecular Delivery Corporation Delivery of drug esters through an inhalation route
US20080038363A1 (en) * 2001-05-24 2008-02-14 Zaffaroni Alejandro C Aerosol delivery system and uses thereof
JP4795637B2 (ja) * 2001-09-28 2011-10-19 カーブ テクノロジー，インコーポレイティド 鼻ネブライザー
CA2482928A1 (en) * 2002-04-18 2003-10-30 Cv Therapeutics, Inc. Method of treating arrhythmias comprising administration of an a1 adenosine agonist with a beta blocker, calcium channel blocker or a cardiac glycoside
US8245708B2 (en) 2002-05-07 2012-08-21 The Research Foundation Of State University Of New York Methods, devices and formulations for targeted endobronchial therapy
US7607436B2 (en) 2002-05-06 2009-10-27 The Research Foundation Of State University Of New York Methods, devices and formulations for targeted endobronchial therapy
EP1515768B1 (en) 2002-05-07 2013-11-06 The State University of New York at Stony Brook Devices for targeted endobronchial therapy
WO2004060351A2 (en) 2002-12-31 2004-07-22 Nektar Therapeutics Pharmaceutical formulation with an insoluble active agent for pulmonary administration
US20050009776A1 (en) * 2003-04-24 2005-01-13 Aderis Pharmaceuticals, Inc. Method of treating atrial fibrillation or atrial flutter
WO2005018635A2 (en) * 2003-08-07 2005-03-03 Cardiome Pharma Corp. Ion channel modulating activity i
EP1755623A4 (en) * 2004-05-21 2007-10-17 Transave Inc TREATMENT OF LUNG DISEASES AND BEFORE A PULMONARY DISEASE
TWI396541B (zh) 2005-10-10 2013-05-21 Boehringer Ingelheim Int 用於治療呼吸疾病之新穎藥物組合
ITMI20051999A1 (it) * 2005-10-21 2007-04-22 Eratech S R L Formulazioni inalatorie di farmaci in fora di polvere secca per somministrazione come tale o con nebulizzatore e dotate di elevata erogabilita' respirabilita' e stabilita'
ES2596263T3 (es) 2006-10-25 2017-01-05 Novartis Ag Aparato de dispersión de polvo
WO2008066745A1 (en) 2006-11-22 2008-06-05 Reliant Pharmaceuticals, Inc. Prophlyaxis and treatment of atrial fibrillation with omega-3 fatty acids
JP5730316B2 (ja) * 2008-09-23 2015-06-10 ラボラトリー スキン ケア インコーポレイテッド 活性剤を充填した、均一、硬質、球状のナノ多孔質リン酸カルシウム粒子の製造方法
ES2750359T3 (es) 2009-03-18 2020-03-25 Incarda Therapeutics Inc Dosis unitarias, aerosoles, kits y procedimientos para tratar afecciones cardíacas mediante administración pulmonar

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070122353A1 (en) 2001-05-24 2007-05-31 Hale Ron L Drug condensation aerosols and kits
US20060034847A1 (en) 2004-08-11 2006-02-16 Yun Anthony J Methods of treating a subject for a condition
WO2007050347A1 (en) 2005-10-21 2007-05-03 Merck & Co., Inc. Potassium channel inhibitors
WO2008036247A1 (en) 2006-09-18 2008-03-27 Vitae Pharmaceuticals, Inc. Renin inhibitors
WO2008072190A2 (en) 2006-12-15 2008-06-19 The Procter & Gamble Company Compositions of azimilide dihydrochloride
WO2008134630A1 (en) 2007-04-30 2008-11-06 Apt Pharmaceuticals Dexrazoxane compounds for cardioprotection
US20080275036A1 (en) * 2007-05-02 2008-11-06 Apt Pharmaceuticals, Inc. Prevention and treatment of cardiac conditions
WO2010019914A2 (en) 2008-08-14 2010-02-18 The Uab Research Foundation Anti-arrhythmia agents, methods of their use, methods for their identification, and kits thereofre
WO2010022259A1 (en) 2008-08-22 2010-02-25 Milestone Pharmaceuticals Inc. Short acting benzothiazepine calcium channel blockers and uses thereof

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BORLAK ET AL.: "Metabolism of Verapamil in Cultures of Rat Alveolar Epithelial Cells and Pharmacokinetics After Administration By Intravenous and Inhalation Routes.", DRUG METABOLISM AND DISPOSITION., vol. 33, no. 8, 2005, pages 1108 - 1114, XP055094279 *
See also references of EP2413902A4
TWISS ET AL.: "Efficacy of Calcium Channel Blockers as Maintenance Therapy for Asthma", BRITISH J OF CLINICAL PHARMACOLOGY, November 2001 (2001-11-01)

Cited By (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10045939B2 (en) 2009-03-18 2018-08-14 Incarda Therapeutics, Inc. Unit doses, aerosols, kits, and methods for treating heart conditions by pulmonary administration
GB2542064A (en) * 2015-01-20 2017-03-08 Incarda Therapeutics Inc Unit aerosol doses for anticoagulation
WO2016118625A1 (en) * 2015-01-20 2016-07-28 Incarda Therapeutics, Inc. Unit aerosol doses for anticoagulation
US10668015B2 (en) 2015-01-20 2020-06-02 Incarda Therapeutics, Inc. Unit aerosol doses for anticoagulation
GB2542064B (en) * 2015-01-20 2020-11-18 Univ California Unit aerosol doses for anticoagulation
RU2731918C2 (ru) * 2015-04-14 2020-09-09 Майлстоун Фармасьютикалз Инк. Хорошо растворимые в воде соли фенилалкиламина - быстродействующего блокатора кальциевых каналов и их применение
EP4428119A3 (en) * 2015-04-14 2024-11-13 Milestone Pharmaceuticals Inc. Highly water-soluble salts of a short acting phenylalkylamine calcium channel blocker and uses thereof
EP3283067A4 (en) * 2015-04-14 2018-12-05 Milestone Pharmaceuticals Inc. Highly water-soluble salts of a short acting phenylalkylamine calcium channel blocker and uses thereof
EP3689344A1 (en) * 2015-04-14 2020-08-05 Milestone Pharmaceuticals Inc. Highly water-soluble salts of a short acting phenylalkylamine calcium channel blocker and uses thereof
AU2016249030B2 (en) * 2015-04-14 2020-08-27 Milestone Pharmaceuticals Inc. Highly water-soluble salts of a short acting phenylalkylamine calcium channel blocker and uses thereof
US10660578B2 (en) 2016-02-01 2020-05-26 Incarda Therapeutics, Inc. Combining electronic monitoring with inhaled pharmacological therapy to manage cardiac arrhythmias including atrial fibrillation
US10441537B2 (en) 2017-05-10 2019-10-15 Incarda Therapeutics, Inc. Unit doses, aerosols, kits, and methods for treating heart conditions by pulmonary administration
EP3621616A4 (en) * 2017-05-10 2021-01-13 InCarda Therapeutics, Inc. UNIT DOSES, AEROSOLS, KITS, AND METHODS FOR TREATING HEART CONDITIONS BY PULMONARY ADMINISTRATION
IL270407B1 (en) * 2017-05-10 2023-11-01 Incarda Therapeutics Inc Dosage units, sprays, kits and methods for treating heart conditions through pulmonary administration
IL270407B2 (en) * 2017-05-10 2024-03-01 Incarda Therapeutics Inc Dosage units, sprays, kits and methods for treating heart conditions through pulmonary administration
WO2018209107A1 (en) 2017-05-10 2018-11-15 Incarda Therapeutics, Inc. Unit doses, aerosols, kits, and methods for treating heart conditions by pulmonary administration
US10744087B2 (en) 2018-03-22 2020-08-18 Incarda Therapeutics, Inc. Method to slow ventricular rate
US11007185B2 (en) 2019-08-01 2021-05-18 Incarda Therapeutics, Inc. Antiarrhythmic formulation
US11020384B2 (en) 2019-08-01 2021-06-01 Incarda Therapeutics, Inc. Antiarrhythmic formulation
US12059414B2 (en) 2020-12-17 2024-08-13 Incarda Therapeutics, Inc. Kits and methods for induction of cardioversion in subjects with atrial arrhythmias

Also Published As

Publication number Publication date
AU2010226613A1 (en) 2011-09-29
JP2012520890A (ja) 2012-09-10
US20190060230A1 (en) 2019-02-28
EP3552603B1 (en) 2024-11-06
US20120003318A1 (en) 2012-01-05
JP2015193657A (ja) 2015-11-05
EP3552602A1 (en) 2019-10-16
EP3552602B1 (en) 2025-03-05
CA2755809C (en) 2014-02-18
EP3552603A1 (en) 2019-10-16
ES2750359T3 (es) 2020-03-25
JP2019019139A (ja) 2019-02-07
CA2835771A1 (en) 2010-09-23
ES3003038T3 (en) 2025-03-10
US8974828B2 (en) 2015-03-10
CA2755809A1 (en) 2010-09-23
EP3552603C0 (en) 2024-11-06
JP7071949B2 (ja) 2022-05-19
CA2835771C (en) 2017-01-24
EP3552602C0 (en) 2025-03-05
US20150313842A1 (en) 2015-11-05
ES3036464T3 (en) 2025-09-19
EP2413902A1 (en) 2012-02-08
US10045939B2 (en) 2018-08-14
US20180318213A1 (en) 2018-11-08
JP6715305B2 (ja) 2020-07-01
JP2017160268A (ja) 2017-09-14
EP2413902A4 (en) 2014-02-19
EP2413902B1 (en) 2019-07-17
DK2413902T3 (da) 2019-10-07
PL2413902T3 (pl) 2020-01-31
US20180296480A1 (en) 2018-10-18
AU2010226613B2 (en) 2013-07-25
JP2019203032A (ja) 2019-11-28

Similar Documents

Publication Publication Date Title
US10045939B2 (en) Unit doses, aerosols, kits, and methods for treating heart conditions by pulmonary administration
US10441537B2 (en) Unit doses, aerosols, kits, and methods for treating heart conditions by pulmonary administration
AU2013248242B2 (en) Unit doses, aerosols, kits, and methods for treating heart conditions by pulmonary administration
CA3200432A1 (en) Kits and methods for induction of cardioversion in subjects with atrial arrhythmias
US10744087B2 (en) Method to slow ventricular rate
AU2016256776B2 (en) Unit doses, aerosols, kits, and methods for treating heart conditions by pulmonary administration
HK40013847A (en) Unit doses, aerosols, kits, and methods for treating heart conditions by pulmonary administration
HK40013848A (en) Unit doses, aerosols, kits, and methods for treating heart conditions by pulmonary administration
HK40013848B (en) Unit doses, aerosols, kits, and methods for treating heart conditions by pulmonary administration
HK1166952B (en) Unit doses, aerosols, kits, and methods for treating heart conditions by pulmonary administration
HK1166952A (en) Unit doses, aerosols, kits, and methods for treating heart conditions by pulmonary administration
HK40013847B (en) Unit doses, aerosols, kits, and methods for treating heart conditions by pulmonary administration

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10754091

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2010226613

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2755809

Country of ref document: CA

Ref document number: 2012500945

Country of ref document: JP

Ref document number: 13257249

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2010226613

Country of ref document: AU

Date of ref document: 20100318

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2010754091

Country of ref document: EP